Lifestyle, Diet, and Home Remedies
Psoriasis patients frequently seek complementary and alternative approaches, either alongside or instead of conventional treatment. Given the chronic nature of the disease, it’s understandable that people want to explore every option. But the quality of evidence for most lifestyle interventions varies enormously, from well-powered randomised controlled trials to anecdotal reports. This section summarises the current state of the science.
19.1 Weight Loss — Strong Evidence
Weight loss is the lifestyle intervention with the strongest evidence base in psoriasis. A 2025 systematic review and meta-analysis of 13 RCTs (1,145 participants) published in the Journal of the European Academy of Dermatology and Venereology found that weight-loss interventions produced a mean PASI reduction of 2.5 points more than controls (95% CI: −3.8 to −1.1), and that participants who lost weight were 1.6 times more likely to achieve PASI 75 (Morrow et al., 2025). The meta-analysis included dietary interventions, exercise programmes, and GLP-1 receptor agonist medications (the class of drugs that includes semaglutide/Ozempic). The authors concluded with “high-certainty evidence” that weight-loss interventions improve both psoriasis severity and quality of life. A separate long-term follow-up study found that these benefits persist: patients who maintained weight loss for 64 weeks continued to show reduced psoriasis severity (Jensen et al., 2016).
The biological rationale is well-established. Adipose tissue (body fat) produces pro-inflammatory cytokines including TNF-α and IL-6, which feed into the same inflammatory pathways that drive psoriasis. Obesity also reduces the efficacy of biologic therapies, particularly fixed-dose regimens where patients above 100 kg are less likely to achieve optimal responses. So weight loss can improve treatment response as well (Puig, 2011).
Evidence grade: High. Recommended as adjunct therapy by clinical guidelines.
GLP-1 Receptor Agonists and Psoriasis
GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, liraglutide/Saxenda, tirzepatide/Mounjaro) deserve specific mention. Originally developed for type 2 diabetes, they’ve become widely prescribed for weight loss. For psoriasis patients, they’re interesting for two reasons.
First, the weight loss they produce is substantial (typically 10-15% of body weight), and as discussed above, weight loss directly improves psoriasis. A 2024 retrospective cohort study of over 1,800 psoriasis patients with type 2 diabetes found that those prescribed GLP-1 RAs had significantly lower rates of psoriasis flares requiring treatment escalation compared to patients on other diabetes medications (Hoisnard et al., 2024). Second, GLP-1 RAs may have direct anti-inflammatory effects beyond weight loss. GLP-1 receptors are expressed on immune cells, and preclinical data suggest that GLP-1 signalling suppresses NF-κB activation and reduces TNF-α, IL-6, and IL-17 production (Mehdi et al., 2023).
This is an active and fast-moving research area. If you have psoriasis and are considering weight loss medication, there may be an additional rationale for choosing a GLP-1 RA, though no clinical guideline yet recommends them specifically for psoriasis.
Evidence grade: Moderate (observational + preclinical). No RCTs of GLP-1 RAs for psoriasis as primary indication yet.
19.2 Mediterranean Diet — Moderate Evidence (Growing)
The Mediterranean diet, rich in olive oil, fish, fruits, vegetables, legumes, and whole grains, and low in processed food and red meat, has shown promising results. The first randomised clinical trial specifically evaluating a structured Mediterranean diet programme for psoriasis (the MEDIPSO trial, 2025) found that a 16-week dietitian-guided Mediterranean diet intervention produced a 3.4-point greater PASI reduction than a standard low-fat diet. This improvement was independent of weight loss (Perez-Bootello et al., 2025). The intervention group also showed improvements in HbA1c (a marker of blood sugar control) and anxiety.
Prior to this trial, evidence came mainly from observational studies, including a large French survey of 35,735 participants from the NutriNet-Santé cohort that found an association between severe psoriasis and low adherence to Mediterranean dietary patterns (Phan et al., 2018). The anti-inflammatory properties of the Mediterranean diet (particularly omega-3 fatty acids, polyphenols, and fibre) provide a plausible biological mechanism.
Evidence grade: Moderate, with the first RCT published in 2025. Promising but more trials needed.
19.3 Omega-3 Fatty Acids (Fish Oil) — Mixed Evidence
Fish oil supplementation has been studied multiple times with contradictory results. An 8-week double-blind study of 28 patients found significant improvement in itching, redness, and scaling, but not in the size of patches (Bittiner et al., 1988). A larger double-blind study of 145 patients over 4 months found no benefit compared to placebo (Soyland et al., 1993). A 2025 systematic review concluded that omega-3 fatty acid supplementation “may be associated with improved psoriasis outcomes” but that evidence quality remains low (Li et al., 2025).
Evidence grade: Low to moderate. Conflicting trial results. May have modest benefit as adjunct therapy but is not a standalone treatment.
19.4 Gluten-Free Diet — Conditional Evidence
A gluten-free diet benefits a specific subgroup of psoriasis patients: those who test positive for antigliadin antibodies (a marker of gluten sensitivity). In one study, 73% of antibody-positive patients saw significant PASI improvement after 3 months on a gluten-free diet, while none of the antibody-negative patients improved (Michaëlsson et al., 2000). A 2018 study by Kolchak et al. found 56% and 36% PASI improvement in patients with very high and high antigliadin antibody levels respectively after one year on a gluten-free diet (Kolchak et al., 2018).
For psoriasis patients without gluten sensitivity, the available evidence shows no benefit from a gluten-free diet. Screening psoriasis patients for coeliac disease markers may identify the subset who could benefit.
Evidence grade: Moderate for antigliadin-positive patients. No evidence of benefit for patients without gluten sensitivity.
19.5 Probiotics and the Gut Microbiome — Emerging but Early
Given the emerging research on the gut-skin axis (discussed in Section 6.5), probiotics and prebiotics are attracting interest. A 2025 systematic review found that probiotic and prebiotic supplementation “may be associated with improved psoriasis outcomes,” but the number of clinical trials is small and their methodologies are heterogeneous (Li et al., 2025). This area is biologically plausible but needs substantially more clinical data before anyone can make firm recommendations.
Evidence grade: Very low. Biologically plausible but insufficient clinical trial data.
19.6 Vitamin D Supplementation — Insufficient Evidence
Oral vitamin D supplementation has biological plausibility: topical vitamin D analogues (calcipotriol) are a first-line psoriasis treatment, vitamin D deficiency is common in psoriasis patients, and the latitudinal prevalence gradient suggests a role for UV/vitamin D. But a 2023 systematic review and meta-analysis of 4 RCTs (333 patients) found no significant improvement in PASI, quality of life scores, or CRP with oral vitamin D supplementation at 3, 6, or 12 months (Dai et al., 2023). No serious adverse effects were reported.
Evidence grade: Low. Biologically plausible but RCT evidence does not support clinical benefit.
19.7 Topical Herbal and Natural Remedies
A 2025 systematic review published in Complementary Therapies in Medicine evaluated herbal medicines for psoriasis using PRISMA guidelines and found that three natural remedies have the strongest clinical evidence (Anheyer et al., 2025):
- Mahonia aquifolium (Oregon grape): A double-blind, placebo-controlled trial of 200 people found that 10% Oregon grape cream produced statistically significant improvement over placebo over 3 months, though it was less effective than standard topical medications.
- Indigo naturalis (a traditional Chinese herbal preparation): Several studies have shown efficacy in psoriasis, with active compounds including indirubin, which inhibits the JAK3/STAT3 pathway and suppresses IL-17A production in laboratory studies.
- Aloe vera: A double-blind study of 60 patients found that 0.5% aloe vera cream produced significantly better results than placebo over 4 weeks. A follow-up replication study of 40 patients failed to confirm this finding. A randomised controlled trial compared aloe vera cream to 0.1% triamcinolone acetonide (a mid-potency topical steroid) and found similar PASI reductions in both groups (7.7 vs 6.6 points), suggesting non-inferiority to a moderate steroid but not superiority to placebo (Choonhakarn et al., 2010).
Other natural remedies commonly discussed include:
- Curcumin (turmeric): Has demonstrated anti-inflammatory properties in laboratory studies, including the ability to modulate TNF-α expression. Clinical trial data in psoriasis is limited to small studies.
- Tea tree oil: No scientific studies have proven effectiveness in psoriasis despite anecdotal reports.
- Apple cider vinegar: No clinical evidence of efficacy; can cause skin damage if applied to cracked or broken skin.
- Colloidal oatmeal baths / Dead Sea salts: May provide symptomatic relief (itching, scaling) but no evidence of disease modification.
Evidence grade: Low to moderate for Oregon grape and indigo naturalis; low for aloe vera; very low or no evidence for tea tree oil, apple cider vinegar, and others.
19.8 Stress Reduction
Stress is a well-documented trigger for psoriasis flares (Section 8.3), and several small studies have explored whether stress-reduction interventions can improve outcomes. Mindfulness-based stress reduction (MBSR) combined with phototherapy showed faster skin clearance than phototherapy alone in one small study. The evidence base remains limited to small trials, though, and no clinical guideline currently recommends specific stress-reduction protocols for psoriasis management.
Evidence grade: Low. Biologically plausible but inadequately studied.
19.9 Alcohol and Smoking Cessation
As discussed in Sections 8.4 and 8.5, smoking and alcohol are established risk factors for psoriasis onset, severity, and treatment resistance. No RCT has directly tested smoking cessation as a psoriasis intervention (for obvious ethical and practical reasons), but observational evidence consistently shows that smokers have worse psoriasis outcomes. Smoking cessation and alcohol reduction are recommended by clinical guidelines for all psoriasis patients, both for skin disease and for the associated cardiovascular and metabolic comorbidities.
Evidence grade: High (observational). Recommended by clinical guidelines.
19.10 Exercise and Physical Activity
Physical activity is an under-recognised but evidence-based adjunct intervention for psoriasis. A 2024 meta-analysis confirmed that psoriasis patients have significantly lower levels of high-intensity exercise than healthy controls, and that this physical inactivity contributes to the elevated cardiovascular and metabolic risk profile discussed in Section 14 (Lopes et al., 2024).
Exercise improves psoriasis severity directly. An interventional study found that a structured exercise programme promoted significant skin clearance, with 50% of participants achieving PASI-50 response at week 20 (Naldi et al., 2024). The biological mechanisms likely include:
- Reduction of systemic inflammation: Exercise decreases circulating TNF-α, IL-6, and CRP, the same inflammatory mediators that drive psoriasis and its comorbidities.
- Weight loss: Exercise-induced weight loss reduces adipokine production and improves biologic treatment response (see Section 19.1).
- Mental health improvement: Exercise reduces depression and anxiety (Section 16), which are both triggers for and consequences of psoriasis.
- Improved insulin sensitivity: Counteracts the metabolic syndrome component of psoriatic comorbidity (Section 14.3).
Practical recommendations: Current evidence supports encouraging moderate-to-vigorous physical activity (150 minutes/week of moderate activity or 75 minutes/week of vigorous activity, consistent with WHO guidelines) as an adjunct to standard psoriasis treatment. Swimming may require attention to chlorine irritation, and you should avoid skin-tight or abrasive clothing to minimise Koebner phenomenon (Section 8.7). Activities that cause excessive friction at characteristic psoriasis sites (elbows, knees) may benefit from protective padding.
Evidence grade: Moderate. Supported by meta-analyses and interventional studies. Exercise is recommended as adjunct therapy for its combined benefits on skin, cardiovascular health, and mental health.
19.11 Summary: The Evidence Hierarchy
| Intervention | Evidence Grade | Best Evidence | Recommended? |
|---|---|---|---|
| Weight loss | High | Multiple RCTs, meta-analyses | Yes — clinical guideline recommendation |
| Smoking cessation | High (observational) | Consistent observational data | Yes — clinical guideline recommendation |
| Alcohol reduction | Moderate (observational) | Observational studies | Yes — clinical guideline recommendation |
| Mediterranean diet | Moderate | 1 RCT (2025) + observational data | Promising — more RCTs needed |
| Gluten-free diet | Moderate (conditional) | Small trials in antibody-positive patients | Only if antigliadin antibody-positive |
| Fish oil / omega-3 | Low–moderate | Conflicting RCTs | May help as adjunct; not standalone |
| Oregon grape cream | Low–moderate | 1 RCT of 200 patients | May help for mild disease |
| Indigo naturalis | Low–moderate | Several studies; preclinical mechanism data | May help; more data needed |
| Aloe vera | Low | Conflicting trial results | Insufficient evidence |
| Curcumin/turmeric | Low | Preclinical + small clinical studies | Insufficient evidence |
| Vitamin D supplementation | Low | 1 meta-analysis of 4 RCTs | Insufficient evidence |
| Exercise (150 min/week) | Moderate | Meta-analyses + interventional | Yes — adjunct therapy |
| Probiotics | Very low | Preliminary only | Insufficient evidence |
| Tea tree oil | None | No clinical studies | No evidence |
| Apple cider vinegar | None | No clinical studies | No evidence; may cause harm |
Important: None of these lifestyle interventions are a substitute for medical treatment in moderate-to-severe psoriasis. The National Psoriasis Foundation advises patients to discuss any complementary approaches with their dermatologist before use, particularly herbal remedies that may interact with prescribed medications.